CAJ | 학술논문

目的：回顾性分析乳腺鳞癌的临床特点及预后。方法分析12例原发性乳腺鳞癌的临床病理特征、治疗方法及生存情况。结果1999年至2014年，我院共治疗20750例乳腺癌患者，其中乳腺鳞癌患者12例（0.058%）。中位发病年龄为52岁；Ⅰ期2例，ⅡA期6例，ⅡB期1例，ⅢA期3例。9例患者予改良根治术，2例予保乳术，1例因局部晚期予全乳切除+淋巴结清除术；4例予术后放疗，9例予术后化疗，3例予内分泌治疗。随访到2014年7月，4例因年代久远失访；1例患者于术后4年发生肺、胸骨、肝和脑的多发转移，行曲妥珠单抗+托瑞米芬治疗1年，带瘤生存4年；1例保乳术8个月后局部复发予乳腺全切后无瘤生存6年；2例分别于术后7个月、3年出现肺转移，经多程化疗分别于11个月后、3年后死亡；余4例均无复发转移，无瘤生存期最长者157个月，短者7个月。结论乳腺鳞癌发生率低，治疗多联合改良根治术和术后辅助治疗。
목적：회고성분석유선린암적림상특점급예후。방법분석12례원발성유선린암적림상병리특정、치료방법급생존정황。결과1999년지2014년，아원공치료20750례유선암환자，기중유선린암환자12례（0.058%）。중위발병년령위52세；Ⅰ기2례，ⅡA기6례，ⅡB기1례，ⅢA기3례。9례환자여개량근치술，2례여보유술，1례인국부만기여전유절제+림파결청제술；4례여술후방료，9례여술후화료，3례여내분비치료。수방도2014년7월，4례인년대구원실방；1례환자우술후4년발생폐、흉골、간화뇌적다발전이，행곡타주단항+탁서미분치료1년，대류생존4년；1례보유술8개월후국부복발여유선전절후무류생존6년；2례분별우술후7개월、3년출현폐전이，경다정화료분별우11개월후、3년후사망；여4례균무복발전이，무류생존기최장자157개월，단자7개월。결론유선린암발생솔저，치료다연합개량근치술화술후보조치료。
Objective To evaluate the clinical characteristics, treatment modalities and prognosis for primary squamous cell carcinoma of the breast. Method Twelve patients of primary squamous cell carcinoma of the breast were retrospectively analyzed. Result Squamous cell carcinoma of the breast accounted for 0.058% (12/20750) of all breast cancer in our hospital from 1999 to 2014. The age of the 12 cases ranged from 31 to 73 years, with a me-dian age of 52 years old. Two patients were in stage I, 6 in stage IIA, 1 in stage IIB and 3 in stage IIIA. Nine pa-tients underwent the modified radical mastectomy, 2 accepted breast-conserving surgery. Four patients received post-operative radiotherapy, 9 were administered with adjuvant chemotherapy and 3 had endocrine therapy. Eight patients had the whole follow-up data, in which 1 patient survived 4 years with stable disease after treated by trastuzumab plus toremifene for multiple metastases after operation. One patient underwent salvage mastectomy for the local re-lapse after breast-conserving surgery and was still alive without disease for 6 years. Two patients died of lung metas-tases, and survived 11 and 36 months after more courses of chemotherapy, respectively. The other four patients were alive without diseases. The follow-up ended at July 2014. The disease-free survival ranged from 7 to 157 months. Conclusion The incidence of primary squamous cell carcinoma of the breast is rare. Combination of mastectomy and adjuvant therapy are needed.